Biomarkers For Detection Of Prostate Cancer Research Articles

Biomarkers for prostate cancer detection and risk stratification.

Although prostate cancer (PCa) is the most commonly diagnosed cancer in men, most patients do not die from the disease. Prostate specific antigen (PSA), the most widely used oncologic biomarker, has revolutionized screening and early detection, resulting in reduced proportion of patients presenting with advanced disease. However, given the inherent limitations of PSA, additional diagnostic and prognostic tools are needed to facilitate early detection and accurate risk stratification of disease. Serum, urine, and tissue-based biomarkers are increasingly being incorporated into the clinical care paradigm, but there is still a limited understanding of how to use them most effectively. In the current article, we review test characteristics and clinical performance data for both serum [4 K score, prostate health index (phi)] and urine [SelectMDx, ExoDx Prostate Intelliscore, MyProstateScore (MPS), and PCa antigen 3 (PCA3)] biomarkers to aid decisions regarding initial or repeat biopsies as well as tissue-based biomarkers (Confirm MDx, Decipher, Oncotype Dx, and Polaris) aimed at risk stratifying patients and identifying those patients most likely to benefit from treatment versus surveillance or monotherapy versus multi-modal therapy.

Effect of Surface Modified Quartz Crystal Microbalance (QCM) on Detection Sensitivity for Prostate Specific Antigen (PSA)

In this work, the surface-modified quartz crystal microbalance (QCM) was utilized for prostate cancer biomarker detection. The electroplating method was highly utilized to modify the QCMs. The influence of electroplating time, corresponding nanostructure formation and surface-modified electrode sensitivity are investigated. The estimated frequency shift for unmodified QCM is 39 Hz, 30-minute modified QCM is 213 Hz, and 60-minute modified QCs is 483 Hz. This method is practically convenient to improve the mass sensitivity of the PSA detector. The mass sensitivity of QCM increased with electroplating time.

The composites of asymmetric Co phthalocyanines-graphitic carbon nitride quantum dots-aptamer as specific electrochemical sensors for the detection of prostate specific antigen: Effects of ring substituents

• .Aptamer - phthalocyanine - quantum dots are used as sensors for prostate antigen. • Electrochemical impedance spectroscopy is employed to determine detection limits. • Low detection limit of 0.27 ng/mL in real sample. Asymmetrical phthalocaynine molecules have been employed in combination with graphitic carbon nitride quantum dots covalently linked to an amine-functionalized aptamer for the electrochemical detection of prostate cancer biomarker. The combination of the phthalocyanine complexes with the quantum dots-aptamer conjugate resulted in an overall improved electrocatalytic ability as well as enhanced signal response. Moreover, results proved one of the complexes being superior over the other functionality wise, indicating the significance of substituent type of the phthalocyanines. The best performing aptasensor showed detection limits as low as 0.23 ng/mL in buffer solutions as well as 0.27 ng/mL in serum samples. Moreover, the sensor showed good stability, reproducibility and repeatability.

DNA precisely regulated Au nanorods/Ag2S quantum dots satellite structure for ultrasensitive detection of prostate cancer biomarker

Currently, metal-enhanced fluorescence (MEF) is an emerging effective technology for sensitive bio-detection. In this report, the distance between Au nanorods (Au NRs) and NIR Ag2S quantum dots (Ag2S QDs) is precisely regulated by DNA with different chain lengths. The experimental results show that the best MEF effect can be obtained when the distance is about 8 nm. Based on the result, Au NRs and Ag2S QDs were modified with DNA at specific distances, which were used for accurate detection of prostate cancer marker PCA3 with high sensitivity and selectivity. And the designed biosensor show a good linear relationship in the 5−500 pM and a low detection limit of 1.42 pM (S/N = 3) for PCA3. Importantly, the designed metal-enhanced NIR fluorescence satellite structure probe have been successfully applied for sensing PCA3 in human serum samples and lysates of prostate cancer cells (1, 5 and 10 cells), which has significant potential in the field of biosensing, biological analysis and clinical diagnosis.

Amperometric Sarcosine Biosensors Based on Electrodeposited Conductive Films Contain Indole‐6‐carboxylic Acid

AbstractSarcosine level in serum is of important clinical significance in distinguishing prostate cancer. This work depicts an amperometric sarcosine biosensor with good anti‐interference performance by electro‐codepositing manganese phosphate, 3,4‐ethylenedioxythiophene (EDOT) and indole‐6‐carboxylic acid (IA) on the glass carbon electrode. The prepared sarcosine biosensor has a wide linear detection range (1–55 μM) with a low detection limit of 0.11 μM. This work provides an anti‐interference approach by controlling the surface charge density of the biosensor to sarcosine sensing, which has great potential to be used as point of care testing (POCT) device for the rapid detection of prostate cancer biomarkers.

Liquid biomarkers in active surveillance.

In the past two decades, new biomarkers for prostate cancer detection and risk prediction have become available for clinical use. While tissue-based gene expression assays offer molecular risk assessment after diagnoses, several serum- and urine-based 'liquid' biomarkers are available for the pre-biopsy setting which may also play a role for active surveillance (AS). The medical literature was queried utilizing PubMed (pubmed.ncbi.nlm.nih.gov) for all relevant original publications describing prostate cancer biomarkers that can be identified in the blood, urine, or semen. Referenced studies must have defined patient inclusion criteria and descriptions of the biomarkers. Included studies investigated the utility of liquid biomarkers for selection or monitoring of men with prostate cancer for active surveillance. PSA is the most common and readily available biomarker for prostate cancer diagnosis and treatment. Contemporary AS guidelines consider diagnostic PSA level in addition to other clinical factors when selecting men for this approach, with most recommending that initial PSA should be under 10 ng/ml. Serum PSA changes are associated with outcomes on AS but are not adequately sensitive so drive men to secondary treatment in isolation. PSA derivates including the Prostate Health Index (phi) and the 4K Score can predict higher grade cancer and may help tailor repeat prostate biopsy strategies, but further data are needed prior to routine clinic use. Several urine-based biomarkers including PCA3 and TMPRSS2:ERG levels have also been studied in the AS setting. Multiple serum- and urine-based liquid biomarkers are available for use in men with prostate cancer. For AS, serum PSA is utilized in part for patient selection as well as to monitor disease over time. Models that incorporate PSA kinetics with other clinical characteristics may help tailor surveillance strategies to reduce disease burden and health care costs over time. Several novel liquid biomarkers demonstrate promise and may eventually have applications for prostate cancer surveillance as well.

The Composites of Asymmetric Co Phthalocyanines-Graphitic Carbon Nitride Quantum Dots-Aptamer as Specific Electrochemical Sensors for the Detection of Prostate Specific Antigen:  Effects of Ring Substituents

Asymmetrical phthalocaynine molecules have been employed, in combination with graphitic carbon nitride quantum dots covalently linked to an amine-functionalized aptamer for the electrochemical detection of prostate cancer biomarker. The combination of these complexes with the quantum dots-aptamer conjugate resulted in overall improved electrocatalytic ability as well as enhanced signal response. Moreover, results proved one of the complexes being superior over the other functionality wise, indicating the significance of substituent type of the phthalocyanines. The best performing aptasensor showed detection limits as low as 0.23 ng/mL in buffer solutions as well as 0.27 ng/mL in serum samples. Moreover, the sensor showed good stability, reproducibility and repeatability.

Clinical utility of current biomarkers for prostate cancer detection.

Although prostate-specific antigen (PSA) remains the most used test to detect prostate cancer (PCa), the limited specificity and an elevated rate of overdiagnosis are the main problems associated with PSA testing. Over the last three decades, a large body of evidence has indicated that PSA screening methods for PCa are problematic, although PSA screening significantly reduces PCa-specific mortality. A number of novel biomarkers have been introduced to overcome these limitations of PSA in the clinical setting. These biomarkers have demonstrated an increased ability to select patients for biopsy and identify men at risk for clinically significant PCa. Although a number of assays require further validation, initial data are promising. Forthcoming results will ultimately determine the clinical utility and commercial availability of these assays. Extensive efforts have recently been made to identify and commercialize novel PCa biomarkers for more effective detection of PCa, either alone or in combination with currently available clinical tools. This review highlights the role of existing and promising serum and urinary biomarkers for the detection and prognostication of PCa before prostate biopsy.

A novel label-free impedimetric immunosensor for sensitive detection of prostate specific antigen using Au nanoparticles/MWCNTs- graphene quantum dots nanocomposite

In this study, a novel impedimetric immunosensor based on Au nanoparticles@ multiwall carbon nanotubes-graphene quantum dots (AuNPs@MWCNTs-GQDs) was designed for the detection of prostate cancer biomarker with high sensitivity and selectivity in human serum. This label-free immunosensor was constructed by glassy carbon electrode surface coating with AuNPs@MWCNTs-GQDs as a signal amplifier and then an antibody against ،Prostate specific antigen)PSA(was immobilized on the modified electrode. The constructed immunosensor was characterized using transmission electron microscopy (TEM), Energy dispersive spectrometry (EDS), X-ray diffraction (XRD), Fourier transform infrared (FTIR), cyclic voltammetry (CV), and electrochemical impedance spectroscopy (EIS) techniques. EIS measurements were applied to investigate the specific immuno-interactions at the immunosensor surface utilizing redox probe [Fe (CN)6]3−/4− to detect prostate specific antigen (PSA). The label-free immunosensor was successfully used to improve the analytical performance significantly and the impedance increment was linearly related to the PSA concentration in a wide linear range of 1–10,000 pg/mL and a low detection limit of 0.48 pg/mL. The responses of the proposed immunosensor in the real samples were compared with the commercial enzyme-linked immunosorbent assay (ELISA) method. The obtained were in good agreement with those obtained by the reference ELISA method. Therefore, this sensor with high sensitivity, selectivity and repeatability, could be utilized for early clinical diagnosis of prostate cancer in the clinical laboratories.

The cost-effectiveness of prostate health index for prostate cancer detection in Chinese men.

Prostate-specific antigen (PSA) and prostate health index (PHI) have been used as biomarkers for prostate cancer detection. In this study, we aimed to evaluate the cost-effectiveness of PHI for prostate cancer detection in Chinese men. We developed a Markov model for Chinese male patient aged 50-75 years old. The PSA strategy was to offer TRUS-PB for all patients with elevated PSA of 4-10 ng/mL. The PHI strategy was to offer PHI for patients with elevated PSA of 4-10 ng/mL. TRUS-PB would only be offered for patients with PHI >35.0. Model inputs were extracted from local data when available. The cost per quality-adjusted life years gained for both strategies were calculated. The incremental cost-effectiveness ratios in relation to the willingness-to-pay (WTP) threshold were compared. One-way sensitivity analysis and probabilistic sensitivity analysis were performed. Cost-effectiveness acceptability curves were also constructed. With a Markov model of 25 screening cycles from age 50 to 75 years, the mean total costs per man were estimated to be USD 27,439 in the PSA strategy and USD 22,877 in the PHI strategy. The estimated effects were estimated to be 15.70 in the PSA strategy and 16.05 in the PHI strategy. The PHI strategy was associated with an expected decrease in cost of USD 4562 and an expected gain of 0.35 QALY, resulting in an ICER of USD -13056.56. The results were shown to be robust upon one-way sensitivity analysis. Upon Monte Carlo simulation, the PHI strategy was more cost-effective for 100% of the iterations. The PHI strategy demonstrated dominance over the PSA strategy regardless of what WTP threshold we use. A PHI-based screening strategy may be more cost-effective than a PSA-based strategy for prostate cancer detection in Chinese men. These results support consideration of a PHI-based approach for prostate cancer in Hong Kong.

Serum Fatty Acid Synthase Level in Patients with Prostate Cancer and Benign Prostatic Hyperplasia

Background: Human Fatty Acid Synthase is highly expressed in many human cancers. Previous studies have shown that this enzyme is expressed at very high levels in prostate cancer and that the growth of prostate cancer cell line can be inhibited by pharmacological inhibitors that target this enzyme. Additionally, some studies have reported that this enzyme is overexpressed not only in tissue, but also in serum of patients with various cancers. The aim of this study was to,evaluate serum levels of this enzyme in patients with prostate cancer and in patients with benign prostatic hyperplasia as well as to investigate whether it can be used as a biomarker for detection of prostate cancer and benign prostatic hyperplasia. Methods: By using an FASN ELISA kit, we measured serum levels of Human Fatty Acid Synthase in 35 patients with prostate cancer and 35 patients with benign prostatic hyperplasia. We also measured serum FASN levels of 35 healthy volunteers enlisted as normal controls. Results: Serum FASN levels in prostate cancer patients were significantly higher than in healthy control subjects, but FASN levels in patients with benign prostatic hyperplasia were not significantly higher than in healthy control subjects. Conclusions: Serum FASN levels are expressed at significantly high levels in human prostate cancer. Serum FASN levels were not expressed at significantly high levels in human benign prostatic hyperplasia. FASN serum levels may be additional biomarker for prostate cancer detection.

In-vitro prostate cancer biomarker detection by directed conjugation of anti-PSCA antibody to super paramagnetic iron oxide nanoparticless

In-vitro prostate cancer biomarker detection by directed conjugation of anti-PSCA antibody to super paramagnetic iron oxide nanoparticless

Circulating MicroRNAs as Biomarkers for Prostate Cancer Detection and Metastasis Development Prediction.

Prostate Cancer (PCa) overdiagnosis and overtreatment, as a consequence of the limited specificity of current detection and prognostication methods, remains a major challenge in clinical practice. Therefore, development and validation of new molecular biomarkers amenable of detecting clinically significant disease is crucial. MicroRNAs (miRNA) deregulation is common in cancer, constituting potential non-invasive biomarkers for PCa detection and prognostication. Herein, we evaluated the screening and prognostic biomarker potential of two onco-microRNAs (miR-182-5p and miR-375-3p) in liquid biopsies (plasma) of PCa patients with clinically localized disease undergoing curative-intent treatment. A first cohort of 98 PCa and 15 normal prostates were used to assess PCa-specificity of miR-182-5p in tissues. A cohort composed of PCa 252 patients and 52 asymptomatic controls allowed for assessment of diagnostic and prognostic value in plasmas. After RNA extraction from tissue and plasma samples, cDNA synthesis specific for miRNAs was performed followed by measurement of miR-182-5p and miR-375-3p relative expression by RT-qPCR, using U6 snRNA gene as reference. MiR-182-5p was significantly overexpressed in PCa tissues (p < 0.0001) and in plasma of PCa patients (p = 0.0020), compared to respective controls. Moreover, miR-182-5p expression identified PCa with AUC = 0.81 (95% CI: 0.725–0.892, p = 0.0001) in tissue and with 77% specificity and 99% NPV (AUC = 0.64, 95% CI: 0.561–0.709, p = 0.0021) in plasma. Both circulating miR-182-5p and miR-375-3p levels associated with more advanced pathologic stage and the former was significantly higher in patients that developed metastasis (p = 0.0145). Indeed, at the time of diagnosis, circulating miR-375-3p levels predicted which patients would develop metastasis, with almost 50% sensitivity, 76% specificity, and a NPV of 89% (AUC = 0.62, 95% CI: 0.529–0.713, p = 0.0149). We conclude that these two circulating miRNAs might be clinical useful as non-invasive biomarkers for detection and prediction of metastasis development at the diagnosis together with clinical variables used in routine practice.

Screening of urine identifies PLA2G16 as a field defect methylation biomarker for prostate cancer detection.

BackgroundProstate cancer (PC) is a multifocal disease. DNA methylation alterations are not restricted to the immediate peritumor environment, but spatially widespread in the adjacent and distant histologically normal prostate tissues. In the current study, we utilized high-throughput methylation arrays to identify epigenetic changes in the urine from men with and without cancer.Design, setting, and participantsDNA urine samples were enriched for methylated fragments using MBD methyl-binding antibodies and applied to high density CytoScanHD arrays. Significant loci were validated using quantitative pyrosequencing and binary logistic regression modeling applied to urine sample analyses in a training (n = 83) and validation approach (n = 84). Methylation alterations in prostate tissues using pyrosequencing at the PLA2G16 locus were examined in 38 histologically normal specimens from men with (TA, n = 26) and without (NTA, n = 12) cancer and correlated to gene expression.ResultsMethylation microarrays identified 3,986 loci showing significantly altered methylation in the urine samples from patients with PC compared to those without (TA vs NTA; p<0.01). These loci were then compared against subjects with their prostates removed to exclude non-prostate cell markers yielding 196 significant regions. Multiple CpGs adjacent to PLA2G16 CpG island showed increased methylation in TA compared to NTA (p<0.01) in a large validation study of urine samples. The predictive accuracy of PLA2G16 methylation at CG2 showed the highest predictive value at 0.8 (odds ratio, 1.37; 95% confidence interval, 1.16–1.62; p<0.001). Using a probability cutoff of 0.065, the sensitivity and specificity of the multivariate model was 92% and 35%. When histologically normal prostate tissues/biopsies from patients with PC (TA) were compared to subjects without cancer, significant hypermethylation of PLA2G16 was noted (odds ratio, 1.35; 95% confidence interval, 1.07–1.71; p = 0.01).ConclusionPLA2G16 methylation defines an extensive field defect in histologically normal prostate tissue associated with PC. PLA2G16 methylation in urine and prostate tissues can detect the presence of PC.

In-vitro prostate cancer biomarker detection by directed conjugation of anti-PSCA antibody to super paramagnetic iron oxide nanoparticless.

Background: The main property of a successful conjugation of antibodies to nanoparticles is keeping the potency of antibody for binding the antigen, and an oriented conjugation can do that. Under such ground, this study was carried out to explore the efficiency of two conjugation methods in binding iron nanoparticles to an antibody produced against PSCA (prostate stem cell antigen) using in vitro labeling of PC3 cells. Methods: In this experimental study, we conjugated dextran-superparamagnetic iron oxide nanoparticles (dexSPIONs) to anti-PSCA antibody by two different methods, including targeting carbohydrate moieties in FC domain and the free amine group of amino acid side chains. Ultimately, Iron staining was done by anti-PSCA antibody-dexSPIONs in PC3 cells to detect antibody binding to the cells. Results: A strong blue dye was induced by iron staining in conjugated dexSPIONs on the membrane of PC3 cells by the former method than the second one. Moreover, cells treated with 20 nm diameters of dexSPIONs showed higher resolution of blue color than those treated with 100 nm nanoparticles. Conclusion: This oriented conjugation method promoted the efficiency of targeting tumor antigens, and the presence of iron particles might enhance MRI image intensity in vivo by targeting PSCA-overexpressing cells in future studies.

An electrochemical biosensor for prostate cancer biomarker detection using graphene oxide-gold nanostructures.

In this paper, a most sensitive electrochemical biosensor for detection of prostate-specific antigen (PSA) was designed. To reach the goal, a sandwich type electrode composed of reduced graphene oxide/ gold nanoparticles (GO/AuNPs), Anti-Total PSA monoclonal antibody, and anti-Free PSA antibody was assembled. The functionalized materials were thoroughly characterized by atomic force microscope spectroscopy, transmission electron microscopy, and X-ray diffraction techniques. The electrochemical properties of each of the modification step were evaluated by cyclic voltammetry and electrochemical impedance spectroscopy. The results presented that the proposed biosensor possesses high sensitivity toward total and free PSA. Furthermore, the fabricated biosensor revealed an excellent selectivity for PSAin comparison to the other tumor markers such as BHCG, Alb, CEA, CA125, and CA19-9. The limit of detection for the proposed electrochemical biosensor was estimated to be around 0.2 and 0.07ng/mL for total and free PSA antigen, respectively.

Vertical flow assays based on core-shell SERS nanotags for multiplex prostate cancer biomarker detection.

Rapid, simultaneous, and sensitive quantification of multiplex prostate biomarkers plays an important role in early diagnosis, especially for obese men and patients. Herein, a surface-enhanced Raman scattering (SERS)-based vertical flow assay (VFA) is presented for simultaneous detection of multiplex prostate cancer biomarkers, such as prostate-specific antigen (PSA), carcinoembryonic antigen (CEA), and alpha-fetoprotein (AFP) on a single test spot. In practice, Raman dyes (RDs) encoded core-shell SERS nanotags instead of conventional gold colloids used in the colorimetric assay are employed in the sensing membrane of SERS based VFAs for multiplex protein detection. Because of the enhanced Raman signal of the core-shell nanostructure and the high surface area to volume ratio (SVR) of the porous sensing membrane, this proposed biosensor shows a wide linear dynamic range (LDR) with detection limits of 0.37, 0.43, and 0.26 pg mL-1 for PSA, CEA, and AFP, respectively, suggesting that this approach can be a good candidate in point of care testing (POCT) for rapid and sensitive biomarker detection and has a huge potential in multiplex analysis and cancer diagnosis.

Abstract A064: Mass spectrometry-based proteomics study makes apolipoprotein E a potential risk factor for prostate cancer

Abstract Proteomics represents an important tool for the identification of new molecular targets for prostate cancer (PCa) tailored therapy. Innovative high-throughput proteomic platforms are now identifying and quantifying new specific and sensitive biomarkers for PCa detection, stratification, and treatment. Formalin-fixed and paraffin-embedded (FF-PE) sections mounted on microscope slides are hard to achieve given the low peptide yield obtained from the slides. Here we performed an innovative protocol for an in-depth quantitative mass spectrometry-based proteomics analysis of FF-PE PCa and benign prostate hyperplasia (BPH) sections, using phase-transfer surfactant-aided extraction/tryptic digestion of FF-PE proteins. Results yielded a list of 50 differential proteins only expressed in PCa samples. Of note, apolipoprotein E (APOE) was highly present in carcinoma samples. Furthermore, to evaluate the clinical significance of APOE in PCa we performed a bioinformatics analysis using the Oncomine database. We identified 16 publicly available gene expression microarray datasets comparing prostate adenocarcinoma versus normal prostate, which met our eligibility criteria. We carried out meta-analysis combining the data from the independent datasets. APOE was ranked by its P-value for every analysis scoring a gene rank and then we obtained a median rank (median P-value rank across datasets). APOE showed a significant upregulation (fold change &amp;gt;1.5, P&amp;lt;0.05) comparing prostate adenocarcinoma vs. normal prostate gland. Accordingly, when extending the bioinformatics analysis to evaluate whole-exome and RNA-seq data using cBioportal, the most frequent genetic alteration found for APOE was amplification. RNA-seq data also confirmed a significant upregulation for APOE (P&amp;lt;0.05). We thus identify APOE as a key target in PCa, ascertaining it as a potential risk factor for this disease. Citation Format: Juan Bizzotto, Sofia Lage Vickers, Alejandra Paez, Carlos Scorticati, Javier Cotignola, Pia Valacco, Osvaldo Mazza, Elba Vazquez, Geraldine Gueron. Mass spectrometry-based proteomics study makes apolipoprotein E a potential risk factor for prostate cancer [abstract]. In: Proceedings of the AACR Special Conference: Prostate Cancer: Advances in Basic, Translational, and Clinical Research; 2017 Dec 2-5; Orlando, Florida. Philadelphia (PA): AACR; Cancer Res 2018;78(16 Suppl):Abstract nr A064.

MiR-27a in serum acts as biomarker for prostate cancer detection and promotes cell proliferation by targeting Sprouty2.

Prostate cancer (PCa) exhibits a high incidence among men, but there is no effective and non-invasive biomarker for the diagnosis of PCa, and the pathogenesis of PCa remains unclear. The present study identified that miR-27a was significantly overexpressed in the tumor tissues and sera of patients with PCa. In addition, high serum levels of miR-27a were correlated with poor survival in patients with PCa. Receiver-operating characteristic curves analysis demonstrated that the serum levels of miR-27a exhibited a high area under the curve value. Furthermore, miR-27a mimics or inhibitors significantly promoted or repressed the proliferation of PCa cells, respectively. In addition, it was identified that the expression of Sprouty2 (SPRY2) was inversely correlated with the expression of miR-27a in PCa tissues. The knockdown or overexpression of SPRY2 promoted or suppressed the proliferation of PCa cells, respectively, and the overexpression of SPRY2 inhibited the increased proliferation and cell cycle distribution of PCa cells mediated by miR-27a mimics. Taken together, these data indicated that the serum levels of miR-27a may be a novel and non-invasive biomarker for the diagnosis and prognosis of patients with PCa, and miR-27a/SPRY2 may be a therapeutic target for the treatment of PCa.

Potentiometric Sensors Based on Molecularly Imprinted Polymers for the Detection of Sarcosine

Cancer is the leading cause of death in economically developed countries and the second leading cause of death in developing countries. Prostate cancer (PCa) is the second most diagnosed cancer and the sixth leading cause of death in men worldwide. PCa incidence is 2 to 5 times higher in developed countries as a result of variations in risk factors and diagnostic practices. PCa new cases represent between 6-14% of all global cancer deaths in 2008. In 2013, malignant tumors were ranked in third place as the cause of death in men (10.5%) in Mexico and the most frequent was PCa (16.3%). PCa mortality increased steadily by 2% per year from 1980 to 2011. The incidence varies due to the practice of prostate-specific antigen (PSA) screening and prostate biopsy. In Latin America, the early detection of PCa is very low and it gets frequently detected in advanced stages. Since the introduction of PSA test in 1986, detection and prevention had been improved, but it is still common to found false positive and false negative results. For PCa detection, it is commonly used ELISA test for PSA screening, digital rectal exam for physical inspection of the prostate and the biopsy to confirm or discard the presence of cancer cells. ELISA test is highly sensitive and specific but also its cost is expensive due to the need for natural specific antibodies, their handling and storage and their low chemical stability. Digital rectal exam (DRE) and biopsy are invasive methods and their main disadvantages are several health risks after the biopsy and the incapacity of PCa detection in areas out of the tumor. Hence, there is a need to develop new technologies with high sensibility and lower response time for the detection of prostate cancer biomarkers during the early stage of the disease. Chemical sensors and biosensors have emerged in recent years as particular interest inside the field of analytical chemistry due to their versatility in clinical assays, drugs detection, food and environmental analysis. An essential part of every sensor is the recognition element, which it gives selectivity towards the analyte in a complex matrix. Biosensors used biological components for recognition such as enzymes, receptors, and antibodies. These allowed a high selectivity but due to their low physical and chemical stability, they cannot be used in rough environments. As an alternative, it can be used biomimetics components, which mimic and selectively bind to a natural molecule. Molecularly imprinted technology is based on the “key-lock” principle, which used a template molecule to create a specific recognition site for it through a polymeric matrix. This molecularly imprinted polymer can be used as a recognition element in chemical sensors for detecting cancer biomarkers. For processing signal, a transducer must be used. Epoxy resins constitute a versatile class characterized by excellent chemical and corrosion resistance, good adhesion to various materials, electrically insulating and easy to fabricate. The addition of powdered fillers like carbonaceous material increases the electrical and heat conductivities of epoxies, providing composite materials that combine a high conductivity. These materials can be used as an all solid-contact electrode and can be used in sensors as a transducer. The present work proposes the construction of selective potentiometric electrodes for the detection of biomarkers related to prostate cancer in early stages of the disease. For that, the use of molecularly imprinted polymers as an element of recognition in a liquid membrane, coupled with a conductive support was investigated. All of this will provide a better response time, limits of detection below concentrations from blood and urine, high selectivity, sensitivity, and reproducibility. Transducers were constructed by using 3 types of carbonaceous materials (graphite, graphene and carbon nanotubes) and epoxy resin. They were characterized by cyclic voltammetry, electrochemical impedance spectroscopy, and four-point probe technique to obtain electrical properties of the materials. A molecularly imprinted polymer was synthesized non-covalent via and analytically characterized. The constructed potentiometric sensor employed an all solid-state electrode for sensing and the effect of pH, selectivity, response time and its potentiometric features were evaluated.